Hepatitis C 
The MD Magazine Hepatitis C condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

NY Insurers to Cover Early HCV Treatment
Under the threat of lawsuits, seven major commercial insurers doing business in New York will now cover direct acting antivirals for patients with HCV infection, as will NY's Medicaid program. The plans will also stop denying coverage to patients who abuse drugs or alcohol.
The US Food and Drug Administration approved a supplemental New Drug Application submitted by drug maker AbbVie for Viekira Pak without ribavirin to treat patients with chronic hepatitis C genotype 1b and compensated cirrhosis.
Why didn't dozens of young patients diagnosed with hepatitis C get treatment in Princeton, NJ? New CDC study offers reasons.
Patients with hepatitis C were two to five times more likely to develop some types of head and neck cancers, according to a study conducted by the University of Texas MD Anderson Cancer Center in Houston.
An Australian physician is sending generic DAAs made in China and India to patients with hepatitis in the US. It's part of an NIH-approved clinical trial.
Layoffs are tough. But, the economic downturn, lower insurance reimbursements, increased business expenses and the expectation that medical practices “do more with less” may make layoffs unavoidable.
A team from Germany found patients with acute HCV infection could be cured in six weeks with DAA treatment, half the recommended time.
A recent study in the United Kingdom looked at the 6-month outcomes of those with hepatitis C cirrhosis on antiviral treatment.
Work being done to treat and cure hepatitis C today could make it almost a non-issue for future generations, thanks to groups like the World Health Organization (WHO) and others putting the focus on parts of the world that need help in this area the most.

Most Popular


$vacMongoViewPlus$ $vAR$